arrow
F

François Lemonnier

mondor university hospital
H指数:32
被引数:4,884

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

二线阿西美单抗 ciloleucel 在不适合移植的大B细胞淋巴瘤中的最终分析

2026-09-230
OAAI
Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort

套细胞淋巴瘤的现代治疗与生存结局:来自REALYSA(LYSA队列)的国家真实世界分析

2026-09-220
OAAI
Incidence and Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy in Light Chain Cardiac Amyloidosis

轻链心脏淀粉样变性患者植入式心律转复除颤器恰当治疗的发病率和预测因素

2026-02-260
PRE
Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma

更正:不同的分子通路驱动单形态上皮表型肠道T细胞淋巴瘤和肠病相关肠道T细胞淋巴瘤。

Leukemia
IF13.4
2025-11-200
OAAI
Invasive Fungal Infections after CD19 CAR T-cell Therapy for B-Cell Lymphoma: a LYSA study from the DESCAR-T Registry

CD19 CAR T细胞疗法治疗B细胞淋巴瘤后的侵袭性真菌感染:一项来自DESCAR-T登记研究的LYSA研究

2025-10-160
OAAI
Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma

分歧的分子通路驱动单形态上皮亲嗜性及肠病相关肠道T细胞淋巴瘤

Leukemia
IF13.4
2025-10-070
OA
Follicular helper T-cell lymphomas with EBV-positive neoplastic cells: a rare scenario with diagnostic implications

滤泡辅助T细胞淋巴瘤伴EBV阳性肿瘤细胞:一种具有诊断意义的罕见情况

2025-08-260
PRE
Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model

阿扎胞苷在患者来源的异种移植滤泡辅助T细胞淋巴瘤模型中诱导p53介导的凋亡

LEUKEMIA
IF13.4
2025-05-200
OAAI
Mutant IDH1 cooperates with NPM1c or FLT3ITD to drive distinct myeloid diseases and molecular outcomes

突变IDH1与NPM1c或FLT3ITD协同作用,驱动不同的髓系疾病和分子结局。

2025-05-160
OA
Scavenging Reactive Oxygen Species by Cerium Oxide Nanoparticles Prevents Death in a Peripheral T Cell Lymphoma Preclinical Mouse Model

氧化铈纳米颗粒清除活性氧可防止外周T细胞淋巴瘤临床前小鼠模型死亡

2025-05-090
PRE
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

TRANSCAR:CD19 CAR T细胞疗法在复发/难治性转化型惰性淋巴瘤中的真实世界疗效

2025-05-050
OAAI
Short-term neurological tolerance of chimeric antigen receptor-T cell therapy for refractory B-cell malignancy in patients with pre-existing cognitive impairment: A retrospective cohort study

异基因抗原受体-T细胞疗法对具有预存认知障碍患者的难治性B细胞恶性病变的短期神经耐受性:一项回顾性队列研究

2025-05-010
OAAI
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

抗PD1疗法在结外NK/T细胞淋巴瘤中的疗效:一项来自LYSA的匹配队列分析

2025-01-200
OA
PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

PRIMAVERA:一项模块化I/II期研究,旨在评估AZD3470(一种蛋白质精氨酸甲基转移酶5 [PRMT5] 抑制剂)在复发/难治性血液恶性肿瘤受试者中的安全性、耐受性和有效性

BLOOD
IF23.1
2024-11-050
PRE
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
2024-10-110
OAAI
Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis

心脏淀粉样变性患者主动脉瓣狭窄的患病率、特征及对预后的影响

2024-07-020
OAAI
Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma
2024-06-190
OAAI
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial( vol 29 , pg 2593 , 2023)

Axicabtagene ciloleucel作为不适合自体干细胞移植的大b细胞淋巴瘤的二线治疗: 一项2期试验 (第29卷,2593页,2023页)

2024-05-140
OAAI